# Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

> **NCT00989963** · PHASE2 · COMPLETED · sponsor: **Lung Biotechnology PBC** · enrollment: 36 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Beraprost Sodium Modified Release

## Key facts

- **NCT ID:** NCT00989963
- **Lead sponsor:** Lung Biotechnology PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-01
- **Primary completion:** 2011-09-13
- **Final completion:** 2011-09-13
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989963, "Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00989963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*